BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
The ambassador study that I presented at ESMO and I presented the updated 45-month follow-up data. I would have done an adaptive design where if the patients had a pathologic complete response, then maybe we don't need the adjuvant approach. But the truth is we don't really know that, right? Because if we think about this as systemic disease, then maybe they do actually have
0
💬
0
Comments
Log in to comment.
There are no comments yet.